Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 3.02
The filing discloses an unregistered sale of 92,960.33 common shares across multiple classes for approximately $1.895 million on August 3, 2026, exempt under Section 4(a)(2) and Regulation D Rule 506. This is a classic dilutive private placement of equity securities to third-party investors, directly matching the Item 3.02 disclosure requirement and the dilutive_issuance event type. The transaction is material as it represents a significant capital raise and equity dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
This is a clear earnings release disclosing Q2 2026 financial results for Transcontinental Realty Investors, Inc. The filing announces net loss of $1.1 million ($0.13 per share) versus net income of $0.2 million ($0.02 per share) in the prior-year quarter, along with detailed consolidated statements of operations and financial highlights. The material swing from profitability to loss, combined with increased operating expenses and decreased interest income, would affect a reasonable investor's assessment of the company's financial condition.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
American Realty Investors announced its operational results for Q2 2026 (quarter ended June 30, 2026) on August 6, 2026, with a news release attached as Exhibit 99.1. The disclosure includes consolidated statements of operations showing a net loss of $1.0 million ($0.06 per share) for Q2 2026 versus net income of $2.8 million ($0.18 per share) in Q2 2025, along with detailed financial highlights and revenue/expense analysis. This is a standard quarterly earnings release material to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-08-06
Item 2.02
DXP Enterprises issued a press release on August 5, 2026, announcing financial results for the second quarter ended June 30, 2026. The disclosure includes detailed quarterly financial highlights (sales of $576.5 million, net income of $28.7 million, diluted EPS of $1.76, and Adjusted EBITDA of $70.4 million), consolidated statements of operations, and balance sheet data. This is a standard earnings release filed under Item 2.02 and furnished as Exhibit 99.1, which is the typical mechanism for quarterly earnings disclosures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
TriSalus issued a press release on August 6, 2026 announcing financial results for Q2 2026 ended June 30, 2026, disclosing revenue of $11.4 million, gross margins of 86.8%, operating losses of $9.8 million, and net loss of $9.2 million, along with full-year 2026 revenue guidance of $54–57 million. This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and operational trajectory.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
Omada Health issued a press release on August 6, 2026 announcing Q2 2026 financial results, including revenue of $88 million (43% YoY growth), gross margin of 73%, and net income of $5 million, with forward guidance for full-year 2026.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-08-06
Item 5.02
Effective January 1, 2027, Wei-Li Shao will be appointed as Chief Executive Officer and Class I director, Sean Duffy will transition to Executive Chairman, and Jeryl Hilleman will be appointed as Lead Independent Director.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
10x Genomics issued a press release on August 6, 2026 announcing financial results for Q2 2026 ended June 30, 2026, disclosing revenue of $151.0 million, gross margin of 74%, operating loss of $19.6 million, and net loss of $17.9 million, along with updated full-year 2026 revenue guidance of $610–$630 million. This is a standard quarterly earnings release filed under Item 2.02 with the press release attached as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release disclosing Nutex Health's financial results for Q2 and H1 2026. The Item 2.02 disclosure explicitly states "On August 6, 2026, Nutex Health Inc. announced its financial and operating results for the second quarter ending June 30, 2026" with a press release furnished as Exhibit 99.1. The exhibit contains detailed financial statements, revenue figures ($427.2M for six months), net income ($112.6M), diluted EPS ($15.87), and operating cash flow ($109.7M), along with management commentary on performance. This is material to investors as it reports significant year-over-year improvements in profitability and cash generation.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
Gevo issued a press release on August 6, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing Q2 revenue of $47 million, a net loss of $(177) million (including a $176 million non-cash impairment charge), and raising full-year 2026 non-GAAP Adjusted EBITDA guidance to more than $60 million from a prior target of $30 million. This is a standard quarterly earnings release with material updates to forward guidance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Cerence Inc. announced financial results for the fiscal quarter ended June 30, 2026, reporting quarterly revenue of $69.6 million (up 12% YoY), GAAP net income of $1.5 million, and Adjusted EBITDA of $13.5 million (up 50% YoY), along with forward guidance for Q4 and full-year FY2026.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-08-06
Item 8.01
The Board authorized a stock repurchase program permitting purchases of up to $30 million of common stock beginning August 10, 2026, representing the company's first-ever share repurchase program and reflecting confidence in the business and commitment to disciplined capital allocation.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
BioLife Solutions issued a press release on August 6, 2026 announcing unaudited financial results for Q2 2026 and the six-month period ended June 30, 2026. The disclosure includes detailed revenue ($28.5M, up 21% YoY), gross margin (64% GAAP, 65% adjusted), operating income, net income ($45.1M including a $42.4M non-cash tax benefit), and adjusted EBITDA metrics. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, the designated Item for results of operations and financial condition.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
StepStone Group Inc. issued a press release on August 6, 2026, announcing its financial results for the first fiscal quarter ended June 30, 2026. The disclosure includes detailed financial highlights, GAAP and non-GAAP results, balance sheet and income statement data, and key operating metrics (AUM, AUA, FEAUM). This is a standard quarterly earnings release furnished under Item 2.02, with the full press release attached as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Silvaco issued a press release on August 6, 2026 announcing its financial results for the second quarter ended June 30, 2026, disclosing GAAP revenue of $17.8 million (up 48% YoY), GAAP operating loss of $4.0 million (improved from $10.1 million loss in Q2 2025), and non-GAAP operating income of $0.6 million (first profitability in nearly two years). The filing explicitly states the press release is attached as Exhibit 99.1 and is incorporated by reference, which is the standard form for earnings releases under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release disclosing Artivion's second quarter 2026 financial results. The Item 2.02 section explicitly states that "Artivion, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026," with the full press release attached as Exhibit 99.1. The disclosure includes revenue of $125.8 million (11% GAAP growth), net loss of $(13.5) million, and adjusted EBITDA of $26.4 million, along with full-year 2026 guidance. This is a material event affecting investor assessment of the company's financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release for Q2 2026 (three and six months ended June 30, 2026). The Item 2.02 disclosure announces financial results including $55 million in revenue (up 56% YoY), gross margin improvements, and net loss of $18 million. The full press release is furnished as Exhibit 99.1, which is the standard format for earnings announcements. The disclosure includes detailed financial statements, guidance for Q3 2026, and management commentary on business performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Century Aluminum issued a press release on August 6, 2026 announcing its second quarter 2026 financial results, including net sales of $752.1 million, net income of $249.3 million, and diluted EPS of $2.39. The filing explicitly states the company "issued a press release announcing its results of operations for quarter ended June 30, 2026" with the press release attached as Exhibit 99.1, which is the standard disclosure mechanism for quarterly earnings releases under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
This is a clear earnings release for Q2 2026 financial results. The Item 2.02 disclosure announces quarterly financial results (Total Net Revenues of $54.7 million, Net Loss of $(30.6) million, Loan Volume of $1.67 billion) with a press release attached as Exhibit 99.1. The filing includes condensed consolidated financial statements, operating metrics, and forward guidance for Q3 2026, all hallmarks of a standard quarterly earnings announcement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
NewtekOne issued a press release on August 6, 2026 announcing its financial and operating results for the quarter ended June 30, 2026, disclosing basic and diluted EPS of $0.48 and $0.47, respectively, along with detailed balance sheet metrics, loan origination data, and profitability ratios. The filing explicitly states the press release is furnished as Exhibit 99.1 and Item 2.02 covers "Results of Operations and Financial Condition," which is the standard Item for earnings releases.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-08-06
Item 2.02
Lyft issued a press release on August 6, 2026 announcing Q2 2026 financial results, reporting Gross Bookings of $5.5 billion (up 23% YoY), Revenue of $1.8 billion (up 16% YoY), Net income of $50.3 million (up 25% YoY), and Adjusted EBITDA of $177.2 million (up 37% YoY), along with record Active Riders of 30.5 million and Q3 2026 guidance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
SkinHealth Systems disclosed its Q2 2026 financial results via press release (Exhibit 99.1) on August 6, 2026, reporting net sales of $72.1 million (down 7.8% YoY), a net loss of $(2.7) million (vs. net income of $19.7 million in Q2 2025), and adjusted EBITDA of $17.0 million. The filing includes comprehensive financial statements, regional metrics, and revised 2026 guidance. This is a standard quarterly earnings release under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
RCI Hospitality Holdings disclosed quarterly financial results for the fiscal quarter ended June 30, 2026, via a press release issued on August 6, 2026, accompanied by the filing of its Form 10-Q. The disclosure includes consolidated statements of income, segment information, and cash flows, with key metrics such as total revenues ($73.9M), EPS ($0.83), and adjusted EBITDA ($16.9M) compared to year-ago periods. This is a standard earnings release under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-08-06
Item 2.02
FedEx Freight disclosed full-year and quarterly financial results for calendar years 2025 and 2024 in Item 2.02, with unaudited consolidated statements of income, balance sheets, and operating statistics attached as Exhibit 99.1. Although the filing emphasizes that this is a "recast" presentation following the June 1, 2026 spin-off and fiscal year-end change (not a restatement), the core disclosure is earnings results—revenue of $8.778 billion and net income of $1.059 billion for 2025, with quarterly breakdowns. This is a material earnings release for a newly independent public company.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
FIGS announced its second quarter 2026 financial results on August 6, 2026, disclosing net revenues of $196.6 million (28.8% YoY growth), net income of $28.4 million ($0.15 diluted EPS), and adjusted EBITDA margin of 18.6%, along with updated full-year 2026 guidance and an increase to the share repurchase authorization.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release disclosing Groupon's financial results for the second quarter ended June 30, 2026. The press release (Exhibit 99.1) announces quarterly revenue, billings, loss from continuing operations, Adjusted EBITDA, and forward guidance for Q3 and full-year 2026. The filing explicitly states "Groupon, Inc. (the 'Company') issued a press release announcing its financial results for its fiscal quarter ended June 30, 2026," which is the hallmark of an earnings_release event under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Roku disclosed its Q2 2026 financial results on August 6, 2026, including total net revenue of $1.35 billion (up 22% YoY), net income of $164 million, and Adjusted EBITDA of $254 million—all record highs. The shareholder letter attached as Exhibit 99.1 presents comprehensive quarterly results across Platform, Advertising, Subscriptions, and Devices segments, making this a standard earnings release disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Sweetgreen issued a press release on August 6, 2026 announcing financial results for its fiscal quarter ended June 28, 2026, disclosing revenue, operating losses, net losses, and adjusted EBITDA alongside forward-looking guidance. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for quarterly earnings disclosures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release for Q2 2026 ended June 30, 2026. The Item 2.02 disclosure announces financial results including revenue of $24.1 million (up 46% YoY), net loss of $14.1 million, and provides updated full-year 2026 guidance. The press release is attached as Exhibit 99.1 and includes detailed financial statements and business highlights, which is the standard format for earnings disclosures under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 6, 2026. The press release (Exhibit 99.1) discloses financial results including net loss of $44.8 million, operating expenses, cash position of $228.0 million, and cash runway guidance into Q3 2027. The filing explicitly states "Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today reported financial results and business highlights for the second quarter ended June 30, 2026." This is material to investors as it provides quarterly financial performance and liquidity information.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
The filing discloses Kodiak AI's second quarter 2026 financial results via a press release issued on August 6, 2026, including Q2 revenue of $3.5 million (91% QoQ growth), operating cash burn of $34.1 million, and free cash flow of negative $38.1 million. The Item 2.02 disclosure and attached Exhibit 99.1 press release are the standard mechanism for reporting quarterly earnings, and the results would materially affect a reasonable investor's assessment of the company's financial performance and cash runway.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-06
Item 2.02
Aflac Incorporated issued a press release on August 6, 2026 reporting its second quarter 2026 financial results, including total revenues of $4.1 billion, net earnings of $825 million ($1.63 per diluted share), and adjusted earnings of $883 million, accompanied by a CFO video presentation and supplemental earnings materials.
View raw filing on EDGAR →
8-K
Earnings release
confidence 75%
filed 2026-08-06
Item 7.01
Vistagen announced topline results from a Phase 2 repeat-dose clinical trial of fasedienol in social anxiety disorder, demonstrating favorable safety, efficacy signals across multiple endpoints, and nominally statistically significant results in the very severe social anxiety subpopulation (LSAS ≥95). For a clinical-stage biopharmaceutical company, clinical trial results on its most advanced product candidate are the primary driver of investor value and directly inform regulatory pathway discussions with the FDA.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 7.01
The filing discloses Power Solutions International's second quarter 2026 financial results, including net sales of $152.5 million, net income of $16.9 million, and diluted EPS of $0.73, along with a 2026 outlook. The press release (Exhibit 99.1) is the core disclosure, containing detailed financial statements, management commentary, and forward-looking guidance—all hallmarks of an earnings release required under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-06
Item 2.02
CareTrust REIT issued a press release on August 6, 2026 announcing its financial results for the second quarter ended June 30, 2026, reporting net income of $89.0 million ($0.38 per diluted share), Normalized FFO of $119.7 million ($0.51 per share), and Normalized FAD of $118.5 million ($0.51 per share), along with updated 2026 full-year guidance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
BARK issued a press release on August 6, 2026 announcing its financial results for fiscal first quarter ended June 30, 2026, disclosing revenue of $78.8 million (down 23.4% YoY), net income of $0.75 million (vs. prior year loss of $7.0 million), and Adjusted EBITDA of $0.6 million. The filing explicitly states the press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes detailed financial statements, segment results, and forward guidance for Q2 and full-year fiscal 2027.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Globus Medical issued a press release on August 6, 2026 reporting its sales and operating results for the three and six month periods ended June 30, 2026. The disclosure includes net sales of $789.6 million (5.9% increase), GAAP net income of $151.6 million, GAAP diluted EPS of $1.10, and non-GAAP diluted EPS of $1.34 (55.8% increase), along with updated 2026 guidance for non-GAAP fully diluted EPS. This is a standard quarterly earnings release with consolidated financial statements and management commentary, clearly falling under Item 2.02 Results of Operations and Financial Condition.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Red Cat Holdings issued a press release on August 6, 2026 disclosing its financial results for the quarter ended June 30, 2026 (Q2 2026), including revenue of $20.2 million (527% Y/Y growth), gross profit of $3.3 million, and gross margin of 16.1%. The filing explicitly states this is furnished under Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes condensed consolidated financial statements and is material to investors assessing the company's operational performance and financial condition.
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-08-06
Item 5.02
The principal disclosed action is the departure of Sheri Savage as Chief Financial Officer effective August 5, 2026, following her notification of intention to retire. Although the filing also mentions Michael Keogh's appointment as her successor (previously disclosed), the focus of this Item 5.02 disclosure is Savage's cessation of officer duties and the terms of her transition agreement, including her continued employment as a non-officer Finance Advisor through May 1, 2027. The departure is material as it involves a named executive officer in a critical financial role.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-06
Item 5.02
The filing discloses the election of Jay Snowden as a Class II director effective immediately, expanding the Board from ten to eleven members. While the disclosure includes compensatory details (annual cash compensation of $100,000 and restricted stock grant of $112,500), the principal action is the appointment of a new director to the Board and assignment to the Audit and Compensation Committees. This is a governance event centered on a person taking a role, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-06
Item 2.02
Abacus Global Management disclosed Q2 2026 financial results with record total revenue of $73.0 million (up 30% year-over-year), adjusted net income of $27.1 million, and adjusted EPS of $0.28, along with forward guidance for Q3 2026 and full-year 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
James Hardie released first quarter FY27 earnings on August 6, 2026, disclosing net sales of $1.475 billion (up 64% YoY), net income of $104 million, and adjusted EBITDA of $422 million, all exceeding original guidance. The company also raised full-year FY27 outlook for pro forma sales growth and adjusted EBITDA growth. This is a standard quarterly earnings release with updated forward guidance, clearly falling under Item 2.02 disclosure of results of operations and financial condition.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 90%
filed 2026-08-06
Item 2.03
Silvaco issued a $10.0 million Senior Convertible Promissory Note to Micron Technology on August 6, 2026, bearing 8.0% simple interest and creating a new direct financial obligation. The Note is convertible into common stock and restricts the Company's ability to incur additional indebtedness up to $50 million.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 3.02
Silvaco issued conversion shares underlying the $10.0 million convertible note in a private placement under Section 4(a)(2) exemption, with the securities offered and sold as unregistered securities creating potential equity dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Nature's Sunshine Products issued a press release on August 6, 2026 announcing Q2 2026 financial results, including net sales of $117.0 million (up 2%), gross profit margin of 73.7% (up 194 basis points), GAAP net income of $3.5 million or $0.19 per diluted share, and adjusted EBITDA of $11.3 million.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-06
Item 5.02
Nature's Sunshine Products appointed Ms. Ruth Perkins as Executive Vice President and Chief Financial Officer, effective September 1, 2026, with a base salary of $575,000 and equity awards totaling approximately $1.65 million.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-06
Item 2.02
Chesapeake Utilities issued a press release on August 6, 2026 announcing Q2 2026 financial results with net income of $25.4 million ($1.05 diluted EPS) and year-to-date results of $84.7 million ($3.51 diluted EPS), along with a presentation for the August 7, 2026 conference call.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Octave Specialty Group issued a press release on August 6, 2026, announcing financial results for the second quarter ended June 30, 2026. The disclosure includes detailed quarterly revenue ($83.0 million, up 51% YoY), net loss to shareholders of $(14.4) million, and segment-level performance metrics. This is a standard earnings release filed under Item 2.02, with the press release incorporated as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
This is a clear earnings release disclosing Q2 2026 financial results for Sanuwave Health, Inc. The press release announces revenue of $9.7 million (down 3% YoY), a net loss of $0.7 million (versus net income of $0.6 million in Q2 2025), and operating loss of $0.3 million (versus operating income of $1.4 million in Q2 2025). The company also withdrew its previously issued fiscal year 2026 guidance due to market conditions and Medicare reimbursement developments. This is material as it discloses significant deterioration in profitability and guidance withdrawal.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Ready Capital Corporation issued an earnings release on August 6, 2026 announcing financial results for the quarter ended June 30, 2026, with the press release attached as Exhibit 99.1. The disclosure includes GAAP loss per common share of $(0.63), distributable loss per common share of $(0.47), balance sheet metrics, portfolio information, and detailed consolidated financial statements. This is a standard quarterly earnings release disclosure under Item 2.02.
View raw filing on EDGAR →